openPR Logo
Press release

Antifibrinolytic Drugs Market Share in Emerging Economies will witness a CAGR of 4.5% through 2026

01-30-2020 01:13 PM CET | Health & Medicine

Press release from: Allied Market Research

Antifibrinolytic Drugs Market

Antifibrinolytic Drugs Market

The global antifibrinolytic drugs market size is expected to reach $19,333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026, in terms of value.

Antifibrinolytic is the class of drugs that is widely used to inhibit fibrinolysis by stopping activation of the proenzyme plasminogen to plasmin. This intrusion is crucial for averting clot degradation in areas rich in the fibrinolysis prone areas such as oral cavity, nasal cavity, and female reproductive tract. Approved antifibrinolytic drugs include Epsilon aminocaproic acid, Tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. In addition, these drugs find their application in surgeries such as cardiovascular surgeries, neurosurgeries, and dental surgeries. Furthermore, antifibrinolytic drugs are used by women to control heavy menstrual flow.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/6279

Considerable increase in road accidents, rise in medical surgeries including cardiac, and dental, and surge in prevalence of angioedema are the major factors that drive the antifibrinolytic drugs market growth. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, blood loss.

The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By type, the gynaecology segment accounted for majority of the market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.

By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals.

Get a purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/6279

North America accounted for most of the Antifibrinolytics Drug Market share in 2018, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant surge in surgeries in this region propels the market growth. However, the Asia-Pacific region is anticipated to grow at the fastest rate due to surge in road accidents and increased usage of these drugs by women to control heavy menstrual flow.

The Major Key Players Are:

o Acic Fine Chems
o Xanodyne Pharmaceuticals
o Aurobindo Pharma Ltd.
o Akorn
o Amerigen Pharms Ltd
o Mylan
o Pfizer (GenMed)
o Sanofi
o Zydus Cadila
o Takeda

Obtain Report Details @ https://www.alliedmarketresearch.com/antifibrinolytic-drugs-market

Key Findings of the Study:

o By indication, the gynecology segment accounted for the highest Antifibrinolytics Drug Market share of 28% in 2018, and is anticipated to grow at the fastest rate during the forecast period.
o By region, North America was the major shareholder and accounted for the highest share of 42% in 2018.
o Asia-Pacific is expected to grow at a CAGR of 6.1% during the forecast period.
o By end user, the hospital & clinics segment dominated the market in 2018 and is anticipated to maintain its dominance during the forecast period.

Similar Reports:

Neurostimulation Devices Market: https://www.alliedmarketresearch.com/neurostimulation-devices-market

Patient Scales Market: https://www.alliedmarketresearch.com/patient-scales-market

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Market Pulse: https://blog.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antifibrinolytic Drugs Market Share in Emerging Economies will witness a CAGR of 4.5% through 2026 here

News-ID: 1914361 • Views: โ€ฆ

More Releases from Allied Market Research

Coffee Franchise Market Shows Steady Growth Trajectory | Size, Share, Trends
Coffee Franchise Market Shows Steady Growth Trajectory | Size, Share, Trends
According to a new report published by Allied Market Research, titled, "Coffee franchise Market," The coffee franchise market was valued at $90.7 billion in 2021, and is estimated to reach $200.3 billion by 2031, growing at a CAGR of 8.3% from 2022 to 2031. ๐†๐ž๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ: https://www.alliedmarketresearch.com/request-sample/A53598 Due to the success of the tested business ideas, there is less risk involved in owning a franchise of a well-known,โ€ฆ
Nutritional Analysis Market: Tracking Health Trends and Industry Growth
Nutritional Analysis Market: Tracking Health Trends and Industry Growth
According to a new report published by Allied Market Research, titled, "Nutritional Analysis Market," The nutritional analysis market was valued at $4.9 billion in 2021, and is estimated to reach $8.2 billion by 2031, growing at a CAGR of 5.5% from 2022 to 2031. ๐€๐œ๐œ๐ž๐ฌ๐ฌ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ: https://www.alliedmarketresearch.com/request-sample/16020 In 2021, the laboratory testing segment accounted for the majority of the total nutritional analysis market. Nutritional analysis isโ€ฆ
North America maintains its position as the largest market for the Furniture industry, with a projected growth rate of 4.9% CAGR through 2030.
North America maintains its position as the largest market for the Furniture ind โ€ฆ
According to a new report published by Allied Market Research, titled, "North America furniture Market by Type and Distribution Channel: Opportunity Analysis and Industry Forecast, 2021-2030,"the North America furniture market size was valued at $ 249,406.5 million in 2020 and is projected to reach $ 400,068.8 million by 2030, registering a CAGR of 4.9% from 2021 to 2030. Furniture is a term that refers to objects used to support human activitiesโ€ฆ
Veterinary Oncology Market Set to Attain USD 297 Million Revenue by 2030, Projecting CAGR of 10.8% from 2021 to 2030; Report
Veterinary Oncology Market Set to Attain USD 297 Million Revenue by 2030, Projec โ€ฆ
The global veterinary oncology market was valued at $0.297 billion in 2020, and is estimated to reach $0.819 billion by 2030, growing at a CAGR of 10.8% from 2021 to 2030. โ€ข CAGR: 10.8% โ€ข Current Market Size: USD 0.297 Billion โ€ข Forecast Growing Region: APAC โ€ข Largest Market: North America โ€ข Projection Time: 2021- 2030 โ€ข Base Year: 2021 ๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ- https://www.alliedmarketresearch.com/request-sample/7504 The global veterinary oncology market is driven by factors such as theโ€ฆ

All 5 Releases


More Releases for Antifibrinolytic

Antifibrinolytic Drugs Market: Report Scope and Market Segmentation 2017 - 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.โ€ฆ
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities By 2025
Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood lossโ€ฆ
Antifibrinolytic Drugs Market Will Generate New Growth Opportunities by 2017 โ€“ โ€ฆ
Eosinophilic asthma is a form of asthma categorized by greater levels of eosinophils in the air passages. Eosinophilic asthma includes contraction and inflammation of the air passages that makes breathing very difficult. Various symptoms are observed in eosinophilic asthma. The symptoms of eosinophilic asthma can be treated by many asthma medications like bronchodilators, anti-inflammatories and asthma inhaling systems. Eosinophilic asthma treatment includes: The allergens can be avoided like certain medications ,smoking,โ€ฆ
Antifibrinolytic Drugs Market Set to Record Exponential Growth by 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.โ€ฆ
Antifibrinolytic Drugs Market Opportunities and Forecasts, 2017 โ€“ 2025
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.โ€ฆ
Antifibrinolytic Drugs Market Foreseen to Grow Exponentially Over 2017 - 2025 : โ€ฆ
Hemostatic agents prevent the blood loss and have the different site of action in complex coagulation and fibrinolysis pathways. Antifibrinolytic drugs inhibit the activation of plasminogen to plasmin preventing the lysis of fibrin and maintaining the clot stability. These Antifibrinolytic drugs prevent excessive bleeding. Tranexamic acid is used when the risk of hemorrhage is high because of increased fibrinolysis. Aprotinin, a proteolytic enzyme inhibitor which acts on plasmin and kallikrein.โ€ฆ